Physician

Ryan Karmouta, MD, MBA

According to 2025 Medicare claims, Ryan Karmouta, MD, MBA (NPI: 1316441066) practices dermatology in the Rockingham County-Strafford County, NH market, with the plurality of this provider's patient population coming from Rockingham, NH. This provider's primary affiliated billing organization is OPTIMA DERMATOLOGY LLC (NPI: 1831187764; TIN: 34-1952521) and primary practice location at 03079-3035.

Karmouta's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,532 traditional Medicare patients, billed 7,267 HCPCS/CPT codes, and received $453,407 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,773 prescription claims across 660 beneficiaries totaling $686,644 in drug costs, led by Skyrizi Pen (Risankizumab-Rzaa). Open Payments data shows 113 records totaling $2,393. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $3,608 to $686,644. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$227K$453K2022 Medicare payment: $49,871 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $242,987 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $453,407 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
2022173812$49,871
20231,0714,503$242,987
20241,5327,267$453,407

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$343K$687K2018 Drug cost: $3,608 (USD; Tot_Drug_Cst)2019 Drug cost: $1,793 (USD; Tot_Drug_Cst)2022 Drug cost: $5,920 (USD; Tot_Drug_Cst)2023 Drug cost: $320,876 (USD; Tot_Drug_Cst)2024 Drug cost: $686,644 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
20181223$3,608
20191424$1,793
2020N/RN/RN/R
2021N/RN/RN/R
202286152$5,920
20234441,035$320,876
20246601,773$686,644

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths431509$75
99203New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more566566$69
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more647849$62
17000Destruction of precancer skin growth, 1 growth560708$37
17003Destruction of precancer skin growth, 2-14 growths3721,764$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Skyrizi PenRisankizumab-Rzaa121,008$247,551
Dupixent PenDupilumab33924$121,963
Clobetasol PropionateClobetasol Propionate1303,782$11,612
TacrolimusTacrolimus351,107$6,296
Triamcinolone AcetonideTriamcinolone Acetonide31310,171$4,128

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.113$2,393E.R. Squibb & Sons, L.L.C.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Ryan Karmouta, MD, MBA?

Tedicare shows public-source Medicare data for Ryan Karmouta, MD, MBA (NPI 1316441066), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ryan Karmouta, MD, MBA have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ryan Karmouta, MD, MBA?

Ryan Karmouta, MD, MBA is linked to OPTIMA DERMATOLOGY LLC (billing NPI 1831187764) in the available physician profile data.

Does Ryan Karmouta, MD, MBA have Open Payments data?

Ryan Karmouta, MD, MBA has 113 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.